🔗 Share this article

Given that America continues making sweeping adjustments to its immunization recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid shots in the global health crisis and has concentrated on potential deaths after Covid immunization in her short tenure at the FDA.

Planned Changes to Pediatric Immunization Schedule

Agency leaders planned to reveal radical revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s vaccine program, according to reports – a major change that would place the US out of step with much of the international standard with insufficient data for benefit. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth person to run the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric immunization guidelines in the US to become more in line with Denmark's approach, a society with universal health coverage and a citizenry roughly the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Background

Høeg has little discernible track record in pharmaceutical research, approval processes or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for running the CDER, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a large organization. She is not an expert in pharmaceutical oversight.”

Previous heads of the center would “understand legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Objectively, she lacks the sort of resume that former directors who headed the center have had.”

This division has an immense workload at the agency, she pointed out.

“Many people just zeroes in on the innovative therapies, but the generic program authorizes numerous generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and each of these have to be looked after,” Dr. Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial leadership aspect to the role, which oversees more than 5,000 personnel. “It’s a enormous management job, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among agency officials on vaccines, a representative said that the “concerns stem from incorrect assumptions”.

“This background aligns with the responsibilities of her position,” the spokesperson said, noting the months Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial expedited therapy clearance system that apparently troubled her former heads. “How are these medications being chosen for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

In general, he remarked, “the agency appears to be shifting towards less stringent rules of most medications, except for immunizations.”

Established Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, history, Howard said. She authored a research paper using unverified volunteer-provided data to determine the incidence of myocarditis after COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current federal leadership featured changing rules for new vaccines and discontinuing “optional” immunizations, she remarked after the election on a online show. At the FDA, Dr. Høeg has allegedly proposed excluding teenage boys from receiving Covid vaccines.

“She is an all-around ideologue who commences with her conclusions and works backwards to retrofit the evidence in a extremely disingenuous, dishonest manner,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|